South Korea's Celltrion says is preferred bidder to acquire pharma company to offset US tariff risk
29/07/2025 02:10
SEOUL, July 29 (Reuters) - South Korean pharmaceutical company Celltrion 068270.KS said on Tuesday that in a bid to offset the risk of U.S. tariffs it had become the preferred bidder to acquire an unnamed pharmaceutical company with a U.S. production facility. Celltrion's CEO said it planned to invest 700 billion won ($503.78 million) in the factory. (Reporting by Joyce Lee and Hyunjoo Jin Editing by Ed Davies) ((joyce.lee@tr.com;))
Recent news on Celltrion
See all newsBrief: Celltrion, Q3 Operating. Profit 510 Billion Won, Up 69% Y/Y
Brief: Celltrion, To Buy 100 Billion Won Worth Of Own Shares
Brief: Celltrion Sets Mid-To-Long Term Shareholder Return Target To One-Third Of Net Profit
South Korean chip stocks rally, tracking US AI gains; Temasek report adds support
Brief: Celltrion Q2 Operating Profit Rises 77.3% Y/Y To 430 Billion Won